EA201891050A1 - Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2 - Google Patents

Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2

Info

Publication number
EA201891050A1
EA201891050A1 EA201891050A EA201891050A EA201891050A1 EA 201891050 A1 EA201891050 A1 EA 201891050A1 EA 201891050 A EA201891050 A EA 201891050A EA 201891050 A EA201891050 A EA 201891050A EA 201891050 A1 EA201891050 A1 EA 201891050A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
mnk2
imidazopyrimidine
pyrazolo
pyrrolo
Prior art date
Application number
EA201891050A
Other languages
English (en)
Other versions
EA034440B1 (ru
Inventor
Пол А. Шпренгелер
Зигфрид Х. Райх
Джастин Т. Эрнст
Стефен И. Веббер
Original Assignee
Эффектор Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эффектор Терапьютикс, Инк. filed Critical Эффектор Терапьютикс, Инк.
Publication of EA201891050A1 publication Critical patent/EA201891050A1/ru
Publication of EA034440B1 publication Critical patent/EA034440B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Настоящее изобретение предоставляет синтез, фармацевтически приемлемые лекарственные препараты и применение соединений, соответствующих формуле I, или их стереоизомеров, таутомеров или их фармацевтически приемлемой солигде в соединениях формулы I A, A, A, A, A, A, A, W, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, Rи индексы "m" и "n" являются такими, как определено в данном описании. Соединения формулы I по настоящему изобретению являются ингибиторами Mnk и обнаруживают полезность во множестве терапевтических применений, включая, но, не ограничиваясь ими, лечение воспаления и различных типов рака.
EA201891050A 2015-10-29 2016-10-28 СОЕДИНЕНИЯ ПИРРОЛО-, ПИРАЗОЛО-, ИМИДАЗОПИРИМИДИНА И ПИРИДИНА, КОТОРЫЕ ИНГИБИРУЮТ Mnk1 И Mnk2 EA034440B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562247966P 2015-10-29 2015-10-29
PCT/US2016/059407 WO2017075412A1 (en) 2015-10-29 2016-10-28 Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2

Publications (2)

Publication Number Publication Date
EA201891050A1 true EA201891050A1 (ru) 2018-11-30
EA034440B1 EA034440B1 (ru) 2020-02-07

Family

ID=57256471

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891050A EA034440B1 (ru) 2015-10-29 2016-10-28 СОЕДИНЕНИЯ ПИРРОЛО-, ПИРАЗОЛО-, ИМИДАЗОПИРИМИДИНА И ПИРИДИНА, КОТОРЫЕ ИНГИБИРУЮТ Mnk1 И Mnk2

Country Status (13)

Country Link
US (2) US20170121339A1 (ru)
EP (1) EP3368533A1 (ru)
JP (1) JP6888006B2 (ru)
KR (1) KR20180070696A (ru)
CN (1) CN108602814A (ru)
AU (1) AU2016343980A1 (ru)
BR (1) BR112018008711A2 (ru)
CA (1) CA3002558A1 (ru)
EA (1) EA034440B1 (ru)
IL (1) IL258867A (ru)
MX (1) MX2018005203A (ru)
SG (1) SG11201803234TA (ru)
WO (1) WO2017075412A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
KR20190117013A (ko) 2017-02-14 2019-10-15 이펙터 테라퓨틱스, 인크. 피페리딘-치환된 Mnk 억제제 및 그와 관련된 방법
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
SG11202104031RA (en) 2018-10-24 2021-05-28 Effector Therapeutics Inc Crystalline forms of mnk inhibitors
CN111253397B (zh) * 2018-11-30 2023-11-14 上海迪诺医药科技有限公司 Mnk抑制剂
US20220251097A1 (en) * 2019-08-01 2022-08-11 St. Jude Childrens's Research Hospital Molecules and methods related to treatment of uncontrolled cellular proliferation
BR112022009563A2 (pt) 2019-11-18 2022-08-02 Jumbo Drug Bank Co Ltd Compostos de pirrolotriazina atuando como inibidor de mnk
EP4171565A2 (en) * 2020-06-30 2023-05-03 4E Therapeutics, Inc. Pyridine-1,5-diones exhibitng mnk inhibition and their method of use
US20240092799A1 (en) * 2020-08-20 2024-03-21 Hepagene Therapeutics (HK) Limited Mnk inhibitors
JP2024516885A (ja) 2021-05-08 2024-04-17 成都嘉葆薬銀医薬科技有限公司 ピロロトリアジン系化合物の塩形、その結晶形及びその製造方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491144A (en) 1991-05-30 1996-02-13 Ciba-Geigy Corporation Substituted diaminophthalimides and analogues
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
EP1912939A1 (en) 2005-08-12 2008-04-23 AstraZeneca AB Metabotropic glutamate-receptor-potentiating isoindolones
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
JP5569956B2 (ja) 2007-03-16 2014-08-13 ザ スクリプス リサーチ インスティテュート 接着斑キナーゼのインヒビター
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
JP2009173629A (ja) 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8609676B2 (en) 2009-08-04 2013-12-17 Merck Sharp & Dohme, Corp. 4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
WO2011106168A1 (en) * 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
JP2013538840A (ja) 2010-10-01 2013-10-17 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換ｎ−（２−アリールアミノ）アリールスルホンアミドを含有する組み合わせ
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9447087B2 (en) 2011-09-23 2016-09-20 University Of Utah Research Foundation Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders
CN104039798B (zh) 2011-12-30 2016-08-24 韩美药品株式会社 具有蛋白激酶抑制活性的噻吩并[3，2-d]嘧啶衍生物
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
GB2508652A (en) 2012-12-07 2014-06-11 Agency Science Tech & Res Heterocyclic piperazine derivatives
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
CA2901527A1 (en) 2013-02-20 2014-08-28 Bayer Pharma Aktiengesellschaft Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors
JP6427115B2 (ja) * 2013-03-05 2018-11-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌などの疾患の処置のためのトリアゾロ［４，５−ｄ］ピリミジン誘導体
TW201605867A (zh) * 2013-11-20 2016-02-16 拜耳製藥公司 噻吩并嘧啶
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
KR20240038145A (ko) * 2015-04-20 2024-03-22 이펙터 테라퓨틱스, 인크. 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제
CN108602805A (zh) 2015-10-29 2018-09-28 效应治疗股份有限公司 Mnk1和mnk2的异吲哚啉、氮杂异吲哚啉、二氢茚酮和二氢氮杂茚酮抑制剂
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
US20170191136A1 (en) 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof

Also Published As

Publication number Publication date
AU2016343980A1 (en) 2018-06-07
KR20180070696A (ko) 2018-06-26
WO2017075412A1 (en) 2017-05-04
MX2018005203A (es) 2018-07-06
BR112018008711A2 (pt) 2018-10-30
JP6888006B2 (ja) 2021-06-16
US20170121339A1 (en) 2017-05-04
EA034440B1 (ru) 2020-02-07
JP2018531972A (ja) 2018-11-01
SG11201803234TA (en) 2018-05-30
US11014926B2 (en) 2021-05-25
IL258867A (en) 2018-06-28
US20190330216A1 (en) 2019-10-31
CA3002558A1 (en) 2017-05-04
EP3368533A1 (en) 2018-09-05
CN108602814A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
EA201891050A1 (ru) Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2
EA201891049A1 (ru) Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2
SA519402217B1 (ar) مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
WO2017087808A8 (en) Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
MD20170016A2 (ru) Аминопиримидиновые соединения в качестве ингибиторов JAK
PH12016500024A1 (en) Bromodomain inhibitor
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
EA201790088A1 (ru) Ингибиторы syk
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
EA201791727A1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии
EA201591781A1 (ru) Химические соединения
PH12015502365A1 (en) Bace1 inhibitors
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
EA201600636A1 (ru) 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды
EA201790603A1 (ru) Ингибиторы гистондеметилазы
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
DOP2015000214A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
MX2017012188A (es) Inhibidores de beta-secretasa 1 (bace1).

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM